share_log

科伦药业(002422.SZ)拟认购控股子公司科伦博泰发行的内资股 认购金额6.03亿元

Colon Pharmaceutical (002422.SZ) plans to subscribe for domestic shares issued by its holding subsidiary Colun Botai with a subscription amount of 603 million yuan

Gelonghui Finance ·  May 7 20:18

Glonghui, May 8 | Colun Pharmaceutical (002422.SZ) announced that in order to further advance the company's development strategy, ensure the orderly development of its holding subsidiary, Sichuan Colunbotai Biomedical Co., Ltd. (“Colunbotai”), maintain the stability of Colunbotai's shareholding structure, and enhance the competitiveness of Colunbotai, plans to issue targeted domestic shares to the company while issuing H shares on the Hong Kong Stock Exchange. The company plans to subscribe for all of its targeted domestic shares. The two parties signed the “Targeted Issuance of Shares Subscription Agreement” on May 8, 2024. The subscription price was determined according to the price of H shares issued by Collumbotai on the Hong Kong Stock Exchange after considering exchange rate factors. The subscription quantity was 4,423,870 shares, and the subscription amount was RMB 602,575,332.70. After the subscription is completed, the company and its wholly-owned subsidiary Colon International Development Co., Ltd. (hereinafter referred to as “Colon International”) will directly hold approximately 54.80% of Colon Botai's shares, and the company will remain the controlling shareholder of Colon Botai.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment